Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
|
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [11] Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
    Yu, Hui
    Brustugun, Odd Terje
    Ekman, Simon
    Botling, Johan
    La Fleur, Linnea
    Micke, Patrick
    Solberg, Steinar
    Berglund, Anders
    Rivard, Christopher
    Hirsch, Fred R.
    CLINICAL LUNG CANCER, 2021, 22 (04) : E555 - E562
  • [12] Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
    Iafolla, Marco A. J.
    Juergens, Rosalyn A.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [13] Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
    Dong, Zhengwei
    Liu, Yiwei
    Jiang, Tao
    Hou, Likun
    Wu, Fengying
    Gao, Guanghui
    Li, Xuefei
    Zhao, Chao
    Wang, Yan
    Yang, Shuo
    Mao, Shiqi
    Liu, Qian
    Li, Yumei
    Xu, Chuan
    Wu, Chunyan
    Ren, Shengxiang
    Zhou, Caicun
    Zhang, Jun
    Hirsch, Fred R.
    JOURNAL OF CANCER, 2020, 11 (03): : 551 - 558
  • [14] Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review
    Bai, Yibing
    Yang, Wenyu
    Kasmann, Lukas
    Sorich, Michael J.
    Tao, Haitao
    Hu, Yi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (02) : 398 - 422
  • [15] Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer
    Kim, Hyojin
    Kwon, Hyun Jung
    Park, Soo Young
    Park, Youngmi
    Park, Eunhyang
    Chung, Jin-Haeng
    PLOS ONE, 2018, 13 (06):
  • [16] Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer
    Chen, Jingyi
    Chen, Yusong
    Feng, Fenglan
    Chen, Cheng
    Zeng, Haikang
    Wen, Shuai
    Xu, Xin
    He, Jianxing
    Li, Jin
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6711 - +
  • [17] MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer
    Grenda, Anna
    Nicos, Marcin
    Szczyrek, Michal
    Krawczyk, Pawel
    Kucharczyk, Tomasz
    Jarosz, Bozena
    Pankowski, Juliusz
    Sawicki, Marek
    Szumilo, Justyna
    Bukala, Paulina
    Milanowski, Janusz
    ONCOLOGY LETTERS, 2019, 17 (06) : 5193 - 5200
  • [18] Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients
    Yan-yan Chen
    Liu-bo Wang
    Hui-li Zhu
    Xiang-yang Li
    Yan-ping Zhu
    Yu-lei Yin
    Fan-zhen Lü
    Zi-li Wang
    Jie-ming Qu
    ChineseMedicalSciencesJournal, 2013, 28 (03) : 147 - 151
  • [19] Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer
    Villaruz, Liza C.
    Blumenschein Jr, George R.
    Otterson, Gregory A.
    Leal, Ticiana A.
    CANCER, 2023, 129 (09) : 1319 - 1350
  • [20] Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype
    Naso, Julia R.
    Wang, Gang
    Pender, Alexandra
    Wong, Selina K.
    Zhu, Jingyao
    Ho, Cheryl
    Ionescu, Diana N.
    Zhou, Chen
    HISTOPATHOLOGY, 2020, 76 (03) : 394 - 403